Answers are grounded in this paper and cite their sources.
Review demonstrates that multiomic integration enhances diagnostic accuracy and biomarker discovery in complex human diseases, highlighting the need for analytical standardization.
Comprehensive molecular characterization may enhance diagnostic assessment in complex human diseases by capturing biological heterogeneity beyond conventional single-layer approaches.This review examines the integration of genomic, proteomic, and epigenetic profiling for precision diagnostics and clinical interpretation.Major advances include comprehensive genomic characterization, high-throughput proteomic profiling, clinically informative epigenetic biomarkers, machine-learning-assisted data integration, and single-cell and spatial multiomics for resolving cellular and tissue-level heterogeneity.Evidence across diverse disease models indicates that integrated molecular data may enhance biomarker identification and provide additional information for disease classification, prognostic assessment, and prediction of therapeutic response; however, comparative measures of diagnostic performance are not consistently available.Proteomic and epigenetic information provides functional and regulatory context to genomic alterations, enabling a more complete representation of disease mechanisms.Current barriers include heterogeneous data formats, batch effects, missing data, limited standardization, high computational and financial requirements, privacy and regulatory concerns, and insufficient clinical validation.Future priorities should focus on harmonized analytical standards, reproducible pipelines, scalable computational infrastructure, improved model interpretability, robust clinical validation, and stronger interdisciplinary collaboration across oncology, rare genetic disorders, neurodegenerative disease, and other clinically heterogeneous conditions in routine practice.Integrative molecular profiling therefore represents a major direction for next-generation diagnostics, with its potential clinical value depending on analytical validation, clinical validity and utility, reproducible implementation, and prospective comparison with established diagnostic pathways.
No takes yet. Share an insight, caveat, or question.
K et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: